Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Akcea Therapeutics

DB:1KA
Snowflake Description

Excellent balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
1KA
DB
$2B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The last earnings update was 38 days ago. More info.


Add to Portfolio Compare Print
  • Akcea Therapeutics has significant price volatility in the past 3 months.
1KA Share Price and Events
7 Day Returns
9.1%
DB:1KA
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-49.3%
DB:1KA
-7.4%
DE Biotechs
-14.2%
DE Market
1KA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Akcea Therapeutics (1KA) 9.1% 9.2% -16.3% -49.3% - -
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • 1KA underperformed the Biotechs industry which returned -7.4% over the past year.
  • 1KA underperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
1KA
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Akcea Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Akcea Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Akcea Therapeutics.

DB:1KA Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.3%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:1KA
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.05
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.048 (1 + (1- 21%) (0.98%))
1.038
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.04
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.038 * 5.44%)
5.25%

Discounted Cash Flow Calculation for DB:1KA using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Akcea Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:1KA DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 5.25%)
2020 351.59 Est @ 58.66% 334.03
2021 495.55 Est @ 40.95% 447.30
2022 637.00 Est @ 28.54% 546.28
2023 763.54 Est @ 19.86% 622.10
2024 868.81 Est @ 13.79% 672.53
2025 951.65 Est @ 9.53% 699.88
2026 1,014.05 Est @ 6.56% 708.54
2027 1,059.41 Est @ 4.47% 703.28
2028 1,091.34 Est @ 3.01% 688.31
2029 1,113.09 Est @ 1.99% 666.97
Present value of next 10 years cash flows $6,089.00
DB:1KA DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $1,113.09 × (1 + -0.39%) ÷ (5.25% – -0.39%)
$19,641.75
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $19,641.75 ÷ (1 + 5.25%)10
$11,769.50
DB:1KA Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $6,089.00 + $11,769.50
$17,858.50
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $17,858.50 / 101.07
$176.69
DB:1KA Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:1KA represents 0.8641x of NasdaqGS:AKCA
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.8641x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 176.69 x 0.8641
€152.68
Value per share (EUR) From above. €152.68
Current discount Discount to share price of €13.58
= -1 x (€13.58 - €152.68) / €152.68
91.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Akcea Therapeutics is available for.
Intrinsic value
>50%
Share price is €13.58 vs Future cash flow value of €152.68
Current Discount Checks
For Akcea Therapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Akcea Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Akcea Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Akcea Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Akcea Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:1KA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $0.29
NasdaqGS:AKCA Share Price ** NasdaqGS (2020-04-08) in USD $15.71
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Akcea Therapeutics.

DB:1KA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:AKCA Share Price ÷ EPS (both in USD)

= 15.71 ÷ 0.29

53.51x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Akcea Therapeutics is overvalued based on earnings compared to the Europe Biotechs industry average.
  • Akcea Therapeutics is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does Akcea Therapeutics's expected growth come at a high price?
Raw Data
DB:1KA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 53.51x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
36.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

DB:1KA PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 53.51x ÷ 36.7%

1.46x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Akcea Therapeutics is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Akcea Therapeutics's assets?
Raw Data
DB:1KA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $5.38
NasdaqGS:AKCA Share Price * NasdaqGS (2020-04-08) in USD $15.71
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:1KA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:AKCA Share Price ÷ Book Value per Share (both in USD)

= 15.71 ÷ 5.38

2.92x

* Primary Listing of Akcea Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Akcea Therapeutics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Akcea Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Akcea Therapeutics has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Akcea Therapeutics expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
36.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Akcea Therapeutics expected to grow at an attractive rate?
  • Akcea Therapeutics's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Akcea Therapeutics's earnings growth is expected to exceed the Germany market average.
  • Akcea Therapeutics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:1KA Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:1KA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 36.7%
DB:1KA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 21.4%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:1KA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:1KA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 978 151 135 3
2023-12-31 618 49 -27 3
2022-12-31 345 -87 -147 3
2021-12-31 224 -204 -223 5
2020-12-31 148 -113 -212 5
2020-04-09
DB:1KA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 489 224 27
2019-09-30 221 -54 -120
2019-06-30 220 -82 -152
2019-03-31 212 -108 -177
2018-12-31 65 -203 -234
2018-09-30 76 -159 -192
2018-06-30 67 -114 -146
2018-03-31 54 -79 -59
2017-12-31 43 -36 -93
2017-09-30 22 -63 -90
2017-06-30 12 -47 -92
2017-03-31 6 -28 -131

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Akcea Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Akcea Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:1KA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Akcea Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1KA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 1.24 2.04 0.29 3.00
2023-12-31 -0.25 0.40 -0.77 3.00
2022-12-31 -1.41 -1.08 -1.88 4.00
2021-12-31 -2.13 -1.83 -2.61 5.00
2020-12-31 -1.93 -1.22 -2.38 5.00
2020-04-09
DB:1KA Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 0.29
2019-09-30 -1.31
2019-06-30 -1.69
2019-03-31 -2.02
2018-12-31 -2.87
2018-09-30 -2.53
2018-06-30 -2.17
2018-03-31 -0.88
2017-12-31 -3.08
2017-09-30 -1.35
2017-06-30 -1.39
2017-03-31

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Akcea Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Akcea Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Akcea Therapeutics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Akcea Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Akcea Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Akcea Therapeutics's year on year earnings growth rate was negative over the past 5 years, however the most recent earnings are above average.
  • Akcea Therapeutics has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • Akcea Therapeutics has become profitable in the last year making it difficult to compare the Europe Biotechs industry average.
Earnings and Revenue History
Akcea Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Akcea Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1KA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 488.54 27.28 181.68
2019-09-30 221.26 -119.98 174.54
2019-06-30 219.88 -152.08 185.55
2019-03-31 211.58 -176.80 177.10
2018-12-31 64.87 -233.61 151.96
2018-09-30 76.36 -192.17 124.69
2018-06-30 67.02 -146.15 87.14
2018-03-31 54.42 -58.95 51.77
2017-12-31 43.40 -93.17 36.98
2017-09-30 21.71 -90.11 25.11
2017-06-30 11.81 -92.34 19.63
2017-03-31 6.09 -131.11 15.48
2016-12-31 -83.22 15.05
2016-09-30 -75.45 15.16 20.83
2016-03-31 -68.40 13.47 43.23
2015-12-31 -61.42 10.55
2014-12-31 -30.02 1.00 29.03

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Akcea Therapeutics has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Akcea Therapeutics used its assets less efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • Unable to establish if Akcea Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to insufficient past data.
X
Past performance checks
We assess Akcea Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Akcea Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Akcea Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Akcea Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Akcea Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Akcea Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Akcea Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.7973264660481E+17x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Akcea Therapeutics Company Filings, last reported 3 months ago.

DB:1KA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 543.00 0.00 463.67
2019-09-30 325.49 0.00 252.69
2019-06-30 368.64 0.00 295.61
2019-03-31 388.86 0.00 321.79
2018-12-31 276.72 0.00 252.61
2018-09-30 281.41 0.00 320.32
2018-06-30 290.40 0.00 381.85
2018-03-31 146.30 0.00 244.94
2017-12-31 167.83 0.00 260.13
2017-09-30 197.84 0.00 286.13
2017-06-30 -82.98 107.51 118.67
2017-03-31 -74.94 91.54 124.52
2016-12-31 -17.75 0.00 7.86
2016-09-30 13.62 0.00 59.46
2016-03-31 42.56 0.00 63.26
2015-12-31 55.27 0.00 64.31
2014-12-31 1.58 0.00
  • Akcea Therapeutics's level of debt (0%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Akcea Therapeutics's debt level has increased without past 5-year debt data.
  • Debt is well covered by operating cash flow (1.2600227332452E+19%, greater than 20% of total debt).
  • Akcea Therapeutics earns more interest than it pays, coverage of interest payments is not a concern.
X
Financial health checks
We assess Akcea Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Akcea Therapeutics has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Akcea Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Akcea Therapeutics dividends.
If you bought €2,000 of Akcea Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Akcea Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Akcea Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:1KA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:1KA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-09

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Akcea Therapeutics has not reported any payouts.
  • Unable to verify if Akcea Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Akcea Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Akcea Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Akcea Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Akcea Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Akcea Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Akcea Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Damien McDevitt
COMPENSATION $10,946,636
AGE 52
TENURE AS CEO 0.6 years
CEO Bio

Dr. Damien McDevitt, Ph.D., has been Chief Executive Officer and Director of Akcea Therapeutics, Inc since March 25, 2020 and October 04, 2018 respectively and served as its Interim Chief Executive Officer since September 23, 2019 until March 25, 2020. Dr. McDevitt served as Chief Business Officer of Ionis Pharmaceuticals, Inc. since June 18, 2018 and provided strategic guidance and lead Ionis’ corporate development activities, including corporate communications, business development, patient advocacy, competitive intelligence and alliance management. Prior to joining Ionis, he served as Senior Vice President of Corporate Development at ACADIA Pharmaceuticals Inc. since December 13, 2017 until 2018. Dr. McDevitt joined ACADIA after more than two decades at GlaxoSmithKline plc, where he was at the forefront of the R&D externalization effort, and involved in more than 70 global business development transactions spanning a variety of therapeutic areas, including neuroscience. Most recently, he was Vice President, Head of Business Development for R&D Extended Therapy Areas, Head of Worldwide Business Development Asia, and Head of its R&D West Coast Satellite. Prior to that, Dr. McDevitt held positions with increasing responsibility within Worldwide Business Development, GSK Ventures and Anti-Infectives Discovery. Dr. McDevitt attended Trinity College in Dublin, Ireland, where he earned his Ph.D. and his undergraduate degree, both in Microbiology.

CEO Compensation
  • Insufficient data for Damien to compare compensation growth.
  • Damien's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Akcea Therapeutics management team in years:

0.6
Average Tenure
50
Average Age
  • The average tenure for the Akcea Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Damien McDevitt

TITLE
CEO & Director
COMPENSATION
$11M
AGE
52
TENURE
0.6 yrs

Alex Howarth

TITLE
Chief Operating Officer
COMPENSATION
$5M
AGE
50
TENURE
0.3 yrs

Paula Soteropoulos

TITLE
COMPENSATION
$7M
AGE
51
TENURE
0.6 yrs

Kyle Jenne

TITLE
Chief Commercial Officer
COMPENSATION
$4M
AGE
43
TENURE
2.9 yrs

Joshua Patterson

TITLE
General Counsel
AGE
43
TENURE
0.1 yrs

Angelyn Lowe

TITLE
Senior Director of Corporate Communications

Jeffrey Goldberg

TITLE
COMPENSATION
$8M
AGE
46
TENURE
0.6 yrs

Louis St. O'Dea

TITLE
Chief Medical Officer
COMPENSATION
$2M
AGE
68
TENURE
4.3 yrs

Bernard Parker

TITLE
VP & Global Franchise Head - TTR

Jared Rhines

TITLE
Senior VP & Head of the Americas
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the Akcea Therapeutics board of directors in years:

3
Average Tenure
64
Average Age
  • The tenure for the Akcea Therapeutics board of directors is about average.
Board of Directors

B. Parshall

TITLE
Chairman of the Board
COMPENSATION
$467K
AGE
65
TENURE
0.3 yrs

Damien McDevitt

TITLE
CEO & Director
COMPENSATION
$11M
AGE
52
TENURE
1.5 yrs

Sandy Smith

TITLE
Independent Director
COMPENSATION
$453K
AGE
72
TENURE
3.1 yrs

Ed Fitzgerald

TITLE
Independent Director
COMPENSATION
$455K
AGE
64
TENURE
2.9 yrs

John Kastelein

TITLE
Member of Cardio Metabolic Advisory Board
AGE
65

Joe Witztum

TITLE
Member of Cardio Metabolic Advisory Board

Sam Tsimikas

TITLE
Member of Cardio Metabolic Advisory Board

Rosanne Crooke

TITLE
Member of Cardio Metabolic Advisory Board

Chris Gabrieli

TITLE
Independent Director
COMPENSATION
$500K
AGE
59
TENURE
4 yrs

Elaine Hochberg

TITLE
Independent Director
COMPENSATION
$461K
AGE
62
TENURE
3.1 yrs
Who owns this company?
Recent Insider Trading
  • Akcea Therapeutics individual insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
25. Mar 20 Sell Damien McDevitt Individual 23. Mar 20 23. Mar 20 -9,417 €10.94 €-103,025
25. Mar 20 Sell Kyle Jenne Individual 23. Mar 20 23. Mar 20 -779 €10.94 €-8,523
25. Mar 20 Sell Louis St. O'Dea Individual 23. Mar 20 23. Mar 20 -3,198 €10.94 €-34,990
25. Mar 20 Sell Joshua Patterson Individual 23. Mar 20 23. Mar 20 -335 €10.95 €-3,667
17. Jul 19 Sell Sarah Boyce Individual 15. Jul 19 15. Jul 19 -1,819 €20.90 €-38,008
X
Management checks
We assess Akcea Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Akcea Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.

Details
Name: Akcea Therapeutics, Inc.
1KA
Exchange: DB
Founded: 2014
$1,460,207,067
101,073,964
Website: http://www.akceatx.com
Address: Akcea Therapeutics, Inc.
22 Boston Wharf Road,
9th Floor,
Boston,
Massachusetts, 02210,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS AKCA Common Stock Nasdaq Global Select US USD 14. Jul 2017
DB 1KA Common Stock Deutsche Boerse AG DE EUR 14. Jul 2017
Number of employees
Current staff
Staff numbers
294
Akcea Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/09 02:09
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/02/27
Last earnings filing: 2020/03/02
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.